Founded by three dermatology drug development experts, Tarian Pharma emerges with a mission: to shield cancer patients from debilitating skin toxicities caused by oncology treatments. The name Tarian, meaning "Shield" in Welsh, becomes our guiding symbol.
Tarian raised a €1.5 million from seed round from private investors and receive a €375,000 grant plus seed financing from BPI France. These funds supported the preclinical program as well as our phase 1 clinical studies in healthy volunteers, validating skin tolerance and systemic safety of Tarian Gel.
A second round of funding raised € 2 Million and enabled the initiation of Phase II clinical trials on cancer patients, assessing the real-world effectiveness of our oncodermatological shield. These studies span 18 months, targeting completion by mid-2026.
Phase 3 is planned in 2027, with a fundraising of €15 million targeted. This final stage will pave the way for market introduction in 2030, delivering a validated, science-driven solution to oncology teams and patients across the globe.
Experience : 25 years of industry experience
Certifications : MD, Dermatologist
Experience : 35 years of industry experience
Certifications : MD, PhD, MBA, Dermatologist
janusz.czernielewski@tarianpharma.com
Experience : 20 years of industry experience
Certifications : PhD, Pharmacist
gareth.winckle@tarianpharma.com
